The U.S. Food and Drug Administration today announced a pilot program designed to streamline communications with sponsors following formal meetings.
Similar Posts
Drug Development Considerations for the Treatment of Neonatal Enterovirus Infection and Congenital Cytomegalovirus Infection–Virtual Public Workshop – 05/07/2024
The Food and Drug Administration is holding a public, two-day workshop entitled Development of Drugs for the Treatment of Congenital Cytomegalovirus (CMV) Infection and Neonatal Enterovirus Infection.Libby Laboratories, Inc. – 708259 – 06/27/2025
CGMP/Finished Pharmaceuticals/Adulteratedwww.portmeds.com – 711585 – 07/16/2025
Unapproved New Drugs/MisbrandedMedi-Fare Drug Pharmaceutical Compounding LLC. Blacksburg, SC. 483 issued 06/06/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 06/06/2025
Short Title (70 char) Medi-Fare Drug Pharmaceutical Compounding LLC. Blacksburg, SC. 483 issued 06/06/2025
FEI Number 3009925820
Firm Name Medi-Fare Drug Pharmaceutical Compounding LLC
Record Type 483PDUFA Performance Reports
PDUFA Performance ReportsLaboratory Information Bulletins
Laboratory Information Bulletins available to the public